CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results